What Does Competitor’s Failure Mean to Alnylam Pharmaceuticals?

• Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is making significant strides in RNA interference (RNAi) therapeutics, focusing on rare diseases and cardiovascular conditions.
• The company's revenue boost is attributed to its diversified drug portfolio, including Amvuttra, which has seen approval in the U.S. and EU.
• Despite challenges such as a negative price-to-earnings (P/E) ratio of -185.46 and a high debt-to-equity ratio of 5.18, Alnylam shows strong financial performance with a current ratio of 2.80.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a prominent player in the field of RNA interference (RNAi) therapeutics. The company focuses on developing treatments for rare diseases and cardiovascular conditions. Alnylam's diverse product lineup includes drugs like Amvuttra, Givlaari, and Oxlumo, which contribute significantly to its revenue. The company is also advancing its cardiovascular research with the ZENITH global Phase 3 trial for zilebesiran.

On October 3, 2025, Garg Pushkal, Alnylam's Executive Vice President and Chief of Research and Development, sold 810 shares of the company's common stock at $450.63 each. Despite this sale, Pushkal still holds 21,751 shares. This transaction comes at a time when Alnylam is experiencing a boost in revenues, driven by its diverse drug portfolio, which helps reduce its reliance on Amvuttra.

Amvuttra, a key revenue driver for Alnylam, has gained approval in the U.S. and EU for treating polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis and ATTR amyloidosis with cardiomyopathy (ATTR-CM). The drug's success is due to new patients starting treatment and others transitioning from Onpattro, Alnylam's first FDA-approved drug for hATTR amyloidosis.

In the first half of 2025, Alnylam's rare disease drugs generated $236.8 million in revenues, a 16% increase from the previous year. This growth highlights the importance of Alnylam's diversified product lineup in maintaining strong financial performance. However, the company faces challenges, as indicated by its negative price-to-earnings (P/E) ratio of -185.46 and a high debt-to-equity ratio of 5.18.

Alnylam's financial metrics, such as a price-to-sales ratio of 24.30 and an enterprise value to sales ratio of 24.37, reflect its valuation in relation to revenue. Despite these challenges, the company's current ratio of 2.80 suggests a strong ability to cover short-term liabilities. Alnylam's ongoing efforts in developing innovative treatments, like the ZENITH trial, aim to strengthen its position in the pharmaceutical industry.

• Kostas Biliouris from BMO Capital sets a price target of $470 for NASDAQ:ALNY, indicating a potential upside of about 3.8%.
• Alnylam showcases its strategic direction and market position at Citi's Biopharma Back to School Conference.
• The company's stock shows slight fluctuations with a current price of $452.13, amidst a backdrop of significant volatility over the past year.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a prominent player in the biopharmaceutical industry, focusing on the development of RNA interference (RNAi) therapeutics. These therapies aim to silence specific genes associated with various diseases. Alnylam's innovative approach places it among the leaders in the sector, competing with other biotech firms like Moderna and BioNTech.

On September 5, 2025, Kostas Biliouris from BMO Capital set a price target of $470 for ALNY. At that time, the stock was trading at $452.81, suggesting a potential upside of about 3.8%. This target reflects confidence in Alnylam's strategic direction and market position, as highlighted during their recent participation in Citi's Biopharma Back to School Conference.

The conference, held on September 3, 2025, in Boston, featured key Alnylam executives like Jeffrey Poulton and Kevin Fitzgerald. They discussed the company's strategic initiatives and developments, providing insights into their future plans. This event, hosted by Citigroup's David Lebowitz, was an opportunity for Alnylam to showcase its advancements in the biopharmaceutical sector.

Currently, ALNY's stock is priced at $452.13, showing a slight decrease of 0.31% or $1.41. The stock has experienced fluctuations, with a daily low of $444.66 and a high of $455.05. Over the past year, ALNY has seen a high of $469.81 and a low of $205.87, indicating significant volatility in its stock price.

Alnylam's market capitalization is approximately $59.26 billion, reflecting its substantial presence in the market. With a trading volume of 264,290 shares on the NASDAQ exchange, the stock remains actively traded. This level of activity underscores investor interest and confidence in Alnylam's potential for growth and innovation in the biopharmaceutical industry.

• Alnylam Pharmaceuticals (NASDAQ:ALNY) reported adjusted earnings of 6 cents per share, surpassing expectations.
• The company's total revenues reached $593.2 million, driven by strong demand for its newly approved drug, Amvuttra.
• Despite positive financial results, ALNY's stock experienced a slight decrease, reflecting the volatile nature of biopharmaceutical stocks.

Alnylam Pharmaceuticals (NASDAQ:ALNY) is a biopharmaceutical company focused on developing RNA interference (RNAi) therapeutics. The company is a leader in this innovative field, aiming to treat genetic diseases by silencing specific genes. Alnylam's competitors include Ionis Pharmaceuticals and Moderna, which also explore genetic-based therapies.

On February 18, 2025, Kevin Joseph Fitzgerald, Alnylam's Chief Scientific Officer, sold 115 shares of the company's stock at $251.60 each. Despite this sale, Fitzgerald still holds 13,120 shares. This transaction comes after Alnylam's strong fourth-quarter 2024 performance, where earnings and revenues exceeded expectations.

Alnylam reported adjusted earnings of 6 cents per share, surpassing the Zacks Consensus Estimate of a 21-cent loss. This is a significant improvement from the previous year's loss of 77 cents per share. The company's total revenues reached $593.2 million, exceeding the anticipated $570 million, driven by a 30% rise in net product revenues.

The increase in product sales is largely due to strong demand for Amvuttra (vutrisiran), a newly approved drug. This contributed to a 35% year-over-year revenue growth from $439.7 million. Despite these positive results, ALNY's stock is currently priced at $250, reflecting a 2.52% decrease.

ALNY's stock has fluctuated between $249.16 and $259.95 during the trading day. Over the past year, it reached a high of $304.39 and a low of $141.98. With a market capitalization of approximately $32.36 billion, ALNY remains a significant player in the biopharmaceutical industry. Today's trading volume is 880,786 shares.

• Alnylam Pharmaceuticals (NASDAQ:ALNY) reported adjusted earnings of 6 cents per share, surpassing expectations.
• The company's total revenues reached $593.2 million, driven by strong demand for its newly approved drug, Amvuttra.
• Despite positive financial results, ALNY's stock experienced a slight decrease, reflecting the volatile nature of biopharmaceutical stocks.

Alnylam Pharmaceuticals (NASDAQ:ALNY) is a biopharmaceutical company focused on developing RNA interference (RNAi) therapeutics. The company is a leader in this innovative field, aiming to treat genetic diseases by silencing specific genes. Alnylam's competitors include Ionis Pharmaceuticals and Moderna, which also explore genetic-based therapies.

On February 18, 2025, Kevin Joseph Fitzgerald, Alnylam's Chief Scientific Officer, sold 115 shares of the company's stock at $251.60 each. Despite this sale, Fitzgerald still holds 13,120 shares. This transaction comes after Alnylam's strong fourth-quarter 2024 performance, where earnings and revenues exceeded expectations.

Alnylam reported adjusted earnings of 6 cents per share, surpassing the Zacks Consensus Estimate of a 21-cent loss. This is a significant improvement from the previous year's loss of 77 cents per share. The company's total revenues reached $593.2 million, exceeding the anticipated $570 million, driven by a 30% rise in net product revenues.

The increase in product sales is largely due to strong demand for Amvuttra (vutrisiran), a newly approved drug. This contributed to a 35% year-over-year revenue growth from $439.7 million. Despite these positive results, ALNY's stock is currently priced at $250, reflecting a 2.52% decrease.

ALNY's stock has fluctuated between $249.16 and $259.95 during the trading day. Over the past year, it reached a high of $304.39 and a low of $141.98. With a market capitalization of approximately $32.36 billion, ALNY remains a significant player in the biopharmaceutical industry. Today's trading volume is 880,786 shares.